Home
Clinical Trials
Treatment ResistAnt Depressio...

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Last Updated: 2026-02-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-11

Study Completion Date

2029-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)

NCT01898429

Treatment Resistant Depression Depressive Disorder, Treatment-Resistant Depression, Bipolar

COMPLETED NA

Study of Transcranial Direct Current Stimulation (tDCS) as add-on Treatment for Resistant Major Depression

NCT01428804

Resistant Major Depression

COMPLETED PHASE2

Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression

NCT02046330

Major Depressive Disorder Treatment Resistant Depression

RECRUITING NA

European Deep Brain Stimulation (DBS) Depression Study

NCT01331330

Depressive Disorder, Major

COMPLETED NA

Spinal Cord Stimulation for the Treatment of Major Depressive Disorder

NCT03433339

Major Depressive Disorder

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this prospective, multi-centered, double-blind, randomized, delayed-stimulation/ Sham-stimulation controlled 12-month study is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using the Infinity™ Deep Brain Stimulation (DBS) system as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) for adults who are experiencing a Major Depressive Episode (MDE) with inadequate response to 4 or more antidepressant treatments.

In a double-blind fashion, half the subjects will receive active DBS therapy, while half will receive sham stimulation. After the 12-month endpoint, all subjects will be unblinded to their treatment group, and subjects in the control arm will receive active DBS therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Treatment Resistant Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sham-stimulation group

Group will be implanted with DBS system but device is not activated for the first 12 months. After 12 months, this group can receive stimulation.

Group Type SHAM_COMPARATOR

Sham-stimulation

Intervention Type DEVICE

Sham-stimulation

Active-stimulation group

Group will have DBS system activated 2 weeks post-implant.

Group Type ACTIVE_COMPARATOR

Active-stimulation

Intervention Type DEVICE

Active DBS

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sham-stimulation

Intervention Type DEVICE

Active-stimulation

Active DBS

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The patient must be diagnosed with non-psychotic unipolar Major Depressive Disorder.
2. The patient must be in a major depressive episode for ≥12 months or have had at least 3 lifetime depressive episodes.
3. The patient has tried and failed a minimum of four different types of antidepressant treatments as measured by a tool designed for this purpose.
4. Depression medication and treatment regimen must be stable for a minimum of 4 weeks before the first baseline visit

Exclusion Criteria

1. Pregnant or those who plan to become pregnant during study
2. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that could limit participation in the study or interfere with adherence to the study protocol.
3. Current or lifetime history of psychotic features in any Major Depressive Episode.
4. Has an intracranial Central Nervous System disease that impairs motor, sensory or cognitive function or that requires intermittent or chronic medication.
5. Significant acute suicide risk.
6. Diagnosis of Substance Use Disorder or Alcohol Use Disorder without sustained remission (12 months or longer).
7. Current and ongoing use of neurostimulation treatment that may interfere with DBS therapy/system.
8. Treatment with another investigational device or investigational drugs.

Minimum Eligible Age

22 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers